It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
originally posted by: seasonal
a reply to: infolurker
Would bundled care require someone to take less money (profit). If so lobbying against it would be fierce.
abcnews.go.com...
Novartis (NVS -1%) has assuaged investors in Gilead Sciences (GILD +5.2%) that CAR-T pricing may be an issue. It announced that its just-approved Kymriah (tisagenlecleucel) will cost $475K per treatment, toward the low end of analysts' projected range of $400K - 750K.
Opening a new era in cancer care, the Food and Drug Administration on Wednesday approved the first treatment that genetically engineers patients' own blood cells into an army of assassins to seek and destroy childhood leukemia.
If CMS agrees and implements the scheme, then the price should be substantially higher than $475K considering the "life value" of young patients who respond.
It also said that it is working with CMS on an outcomes-based approach to reimbursement that will allow payment for only those ALL patients that respond to treatment by the end of one month.
originally posted by: Bluntone22
a reply to: FyreByrd
Because the government is ran by idiots.
Remember the Wall Street bailout?
People got their bonuses paid for with bailout money.
Fricken idiots.
originally posted by: namehere
a reply to: namehere
my point being that all these high prices come from too much regulation and more regulations to control prices would make it even worse.
originally posted by: namehere
a reply to: namehere
my point being that all these high prices come from too much regulation and more regulations to control prices would make it even worse.
originally posted by: namehere
a reply to: carewemust
price gouging is rare and it only happens when costs are driven up by excessive regulations, if price gouging happens then take legal action instead of regulating the whole industry and punishing innocent businesses and people.
originally posted by: Abysha
originally posted by: namehere
a reply to: namehere
my point being that all these high prices come from too much regulation and more regulations to control prices would make it even worse.
That makes no sense. Regulations are to prevent monopolies and unfair practices. Without them, there would be no competition, just one giant company within 20 years.
Prescription drug prices are skyrocketing in the United States due in large part to government regulations, a new analysis finds.
These regulations allow drug manufacturers to charge monopolistic prices that aren’t opposed by competing market forces, the researchers believe. Drug makers charge high prices for drugs thanks largely to “market exclusivity” regulations
The companies can do this largely unopposed because the nation’s largest health insurers -- Medicare and Medicaid -- aren’t allowed to negotiate prices, he added.
Those insurance programs cover one out of every three Americans, but under federal law must pay whatever price the drug makers charge.
Upon approval of a new drug, the U.S. Food and Drug Administration (FDA) sets a period of market exclusivity that can last from five to 12 years, the authors said. During that period, no low-cost generic version of that drug can be sold.
Exclusivity regulations are being exploited through tactics like “evergreening” and “hard switching,” Sarpatwari said.
“Evergreening” occurs when drug companies renew their market exclusivity for a product by patenting a new version that is slightly different, Sarpatwari said.
According to Gina Moore, assistant dean for clinical and professional affairs with the University of Colorado’s School of Pharmacy and Pharmaceutical Sciences, “We see that consistently with drugs that are about to come off-patent.”
Moore said that “the drug company will make a trivial change to a drug they have on-patent, and then promote that newer medicine as being superior to the earlier version, even though it has limited clinical benefits.”
Sarpatwari explained that in “hard switching,” manufacturers stop selling an older drug about to go generic and replace it with a new high-price market-exclusive product.
“When the generic version of the prior drug goes onto the market, many patients wouldn’t automatically be taken onto it because they’re now prescribed the new product,” Sarpatwari said.
Consumers could fight back against these high prices by refusing to pay them, but that’s not an option for the nation’s largest health insurance plan, he added.
Medicare covers more than 55 million people, and Medicaid programs cover more than 70 million. But federal law prevents the U.S. Centers for Medicare and Medicaid Services from negotiating drug prices with pharmaceutical manufacturers, Sarpatwari said.
Moore pointed out that most other countries allow their government health programs to negotiate drug prices. Americans pay more because their ability to push back is hampered.
Katherine Hempstead is a senior advisor who leads the Robert Wood Johnson Foundation’s work on health insurance coverage. She said, “Some people would probably say we are subsidizing drug development for the rest of the world.”
Sarpatwari and his colleagues said that the FDA needs to apply more stringent requirements on the award and extension of exclusivity rights.
In addition, Congress should reconsider allowing Medicare and Medicaid to negotiate drug prices, rather than forcing the programs to pay whatever pharmaceutical manufacturers demand, the authors stated.
Meanwhile, Hempstead said, other efforts are underway that could help lower drug prices.
Yet the main reason the new kind of pharma companies has taken an interest in this market is that the Orphan Drug Act (ODA) substantially increases the potential profits. Since its passage in 1983, the ODA has governed approval of drugs for rare diseases and has incentivized pharmaceutical innovation via multiple tax breaks and seven years of market exclusivity. Now, though, pharma companies are taking advantage of these incentives to profit from individual patients and private and government insurers. According to EvaluatePharma’s 2015 Orphan Drug Report, this market makes up 20.2% of total global prescription drug sales and is growing by 11.7% annually, nearly double the growth rate of the global prescription drug market overall. Strikingly, 44% of new drugs approved in 2014 had orphan status, with seven of the 10 best-selling drugs being approved under the ODA.
The business model of the exploitative companies profoundly impacts our health care system’s ability to manage costs and provide care. My colleague Erin Fox, director of University of Utah Health Care’s Drug Information Service, recently provided an excellent example in her testimony before the U.S. Senate Special Committee on Aging. In 2015 Valeant acquired the heart drug Isuprel and promptly raised the price for a single vial from $440 to $2,700, citing a responsibility to shareholders to maximize profit. This 600% increase would have cost our hospital $1.6 million each year and forced us to remove it from emergency crash carts.
originally posted by: namehere
a reply to: infolurker
yeah, it exists and i never said it didn't, what i said was the main reason it happens is one of two reasons, the first is when a resource becomes rare and the laws are not enforced and the second reason is when excessive regulations drive up prices thus simulating rarity of a commodity...
i never said there should be no regulations, what i said is that current regulations go too far and endangers our country by driving prices up in every sector of the economy, for rare disease drug development costs are so high and progress is delayed so often because regulations go too far, leaving many hanging for decades.